[PDF] Committee for Medicinal Products for Human Use (CHMP) issues positive opinion for license extension of lenalidomide (Revlimid)

Source:
European Medicines Agency - EMA
Publisher:
European Medicines Agency
Publication date:
15 November 2019

Abstract

The proposed license extension for lenalidomide is in combination with rituximab for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).